Recce Pharma R327G Phase 3 trial reaches key milestone

Podcast: Proactive - Interviews for investors · Proactive

Opublikowano: 2026-10-21

Recce Pharmaceuticals Ltd chief executive James Graham talked with Proactive about the company’s Phase 3 trial of RECCE® 327 Gel, or R327G, for the treatment of diabetic foot infections in Indonesia and the upcoming review of trial data by an independent Data Monitoring Committee. Graham said the study is targeting a significant unmet medical need, highlighting the prevalence of diabetes across Indonesia and the wider ASEAN region and the risk that diabetic ulcers can become infected. He said R327G is being positioned as a potential treatment specifically for diabetic foot ulcer infections. Data from 75 patients has been submitted to the...